{"id":224389,"date":"2024-02-22T16:25:02","date_gmt":"2024-02-22T16:25:02","guid":{"rendered":"https:\/\/bm.dev.synology.me\/?p=224389"},"modified":"2024-02-22T16:25:02","modified_gmt":"2024-02-22T16:25:02","slug":"un-nou-medicament-ofera-speranta-in-lupta-impotriva-cancerului-pancreatic-metastatic","status":"publish","type":"post","link":"https:\/\/bm.dev.synology.me\/?p=224389","title":{"rendered":"Un nou medicament ofer\u0103 speran\u0163\u0103 \u00een lupta \u00eempotriva cancerului pancreatic metastatic"},"content":{"rendered":"<p>\nUn nou medicament numit Nal-IRI a fost aprobat pentru finan\u0163are de c\u0103tre Agen\u0163ia Italian\u0103 pentru Medicamente (AIFA). Nal-IRI utilizeaz\u0103 nanotehnologia pentru a-\u015fi atinge \u0163inta \u015fi a demonstrat o \u00eembun\u0103t\u0103\u0163ire semnificativ\u0103 a ratei de supravie\u0163uire a pacien\u0163ilor cu cancer pancreatic metastatic.<\/p>\n<p>\nEficacitatea Nal-IRI a fost demonstrat\u0103 \u00een cadrul studiului de faz\u0103 III Napoli-1. Studiul a ar\u0103tat c\u0103 Nal-IRI a crescut durata median\u0103 de supravie\u0163uire de la 4,2 la 6,1 luni, cu o reducere de 33% a riscului de deces, conform Il Messaggero.<\/p>\n<p>\nNal-IRI este un medicament destinat trat\u0103rii bolilor rare. Este primul medicament aprobat pentru tratamentul de linia a doua a cancerului pancreatic metastatic.<\/p>\n<p>\nRomano Danesi, profesor de farmacologie la Universitatea din Milano, a declarat c\u0103, din cauza slabei sale vasculariz\u0103ri, acest neoplasm este caracterizat de cantitatea limitat\u0103 de medicament care poate ajunge la celulele tumorale.<\/p>\n<p>\nPentru a ocoli aceast\u0103 limitare, Nal-IRI exploateaz\u0103 tehnologia nanoparticulelor lipozomale.<\/p>\n<p>\nCancerul pancreatic este unul dintre cele mai greu de diagnosticat neoplasme, cu o rat\u0103 de supravie\u0163uire la 5 ani de 11% la b\u0103rba\u0163i \u015fi 12% la femei. Acesta este singurul cancer al tractului gastrointestinal care nu \u015fi-a \u00eembun\u0103t\u0103\u0163it supravie\u0163uirea \u00een 40 de ani.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Un nou medicament numit Nal-IRI a fost aprobat pentru finan\u0163are de c\u0103tre Agen\u0163ia Italian\u0103 pentru Medicamente (AIFA). Nal-IRI utilizeaz\u0103 nanotehnologia pentru a-\u015fi atinge \u0163inta \u015fi a demonstrat o \u00eembun\u0103t\u0103\u0163ire semnificativ\u0103 a ratei de supravie\u0163uire a pacien\u0163ilor cu cancer pancreatic metastatic. Eficacitatea Nal-IRI a fost demonstrat\u0103 \u00een cadrul studiului de faz\u0103 III Napoli-1. Studiul a ar\u0103tat [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[510],"tags":[56981,32260],"class_list":["post-224389","post","type-post","status-publish","format-standard","hentry","category-actualitate","tag-cancer-pancreatic","tag-medicament"],"_links":{"self":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/224389","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=224389"}],"version-history":[{"count":0,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/224389\/revisions"}],"wp:attachment":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=224389"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=224389"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=224389"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}